Respiratory Tract Infection Treatment Market 2028 By Drug, Disease Indication, Distribution Channel and Geography | The Insight Partners

report image

Respiratory Tract Infection Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug (Antibiotics, Non-Steroidal Anti-Inflammatory Drug (NSAIDS), Cough Suppressant, Nasal Decongestant, Others); Disease Indication (Upper Respiratory Tract Infection, Lower Respiratory Tract Infection); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

Report Code: TIPRE00003835 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming


Any infectious disease affecting the upper or lower respiratory tract is referred to as a respiratory tract infection (RTI). The common cold, laryngitis, pharyngitis/tonsillitis, acute rhinitis, acute rhinosinusitis, and acute otitis media are all upper respiratory tract infections (URTIs). Acute bronchitis, bronchiolitis, pneumonia, and tracheitis are examples of lower respiratory tract infections (LRTIs). In primary care, antibiotics are commonly prescribed for RTIs in adults and children.


The "Global Respiratory Tract Infection Treatment Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the respiratory tract infection treatment market with detailed market segmentation by drug, disease indication and distribution channel. The report provides key statistics on the market status of the leading respiratory tract infection treatment market players and offers key trends and opportunities in the market.


  •   Based on drug the market is segmented as, antibiotics, non-steroidal anti-inflammatory drug (NSAIDS), cough suppressant, nasal decongestant, others.
  •   Based on disease indication the market is segmented as, upper respiratory tract infection, lower respiratory tract infection.
  •   Based on distribution channel the market is segmented as, hospital pharmacies, retail pharmacies, and online pharmacies.



  •   Increasing incidences of respiratory disorders and rising prevalence of allergic reactions are the key drivers for the market growth.
  •   Technological advancements in development of respiratory preparations and availability of medicines at lower costs.
  •   Presence of robust pipeline of agents to manage respiratory tract infections.
  •   Growing OTC product demand to treat respiratory infections.


  •   However, risk of possible side effects is expected to restrain the market growth during the forecast period.


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The respiratory tract infection treatment market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the respiratory tract infection treatment market in these regions.

COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.


The report covers key developments in the respiratory tract infection treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from respiratory tract infection treatment market are anticipated to lucrative growth opportunities in the future with the rising demand for respiratory tract infection treatment in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the respiratory tract infection treatment market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  •   Abbott
  •   AstraZeneca
  •   Alembic Pharmaceuticals
  •   Boehringer Ingelheim International GmbH
  •   GlaxoSmithKline plc
  •   Teva Pharmaceutical Industries Ltd
  •   Intas Pharmaceuticals Ltd.
  •   Novartis AG
  •   F. Hoffman La Roche Ltd
  •   Sanofi
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
The List of Companies

- Abbott
- AstraZeneca
- Alembic Pharmaceuticals
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd
- Intas Pharmaceuticals Ltd.
- Novartis AG
- F. Hoffman La Roche Ltd
- Sanofi
- Procter and Gamble
- Cipla Inc
- Dr. Reddy's Laboratories
- Johnson and Johnson Private Limited
- Bayer
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market

Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount